Expression of MMP-2, MMP-9, and urokinase-type plasminogen activator in cervical intraepithelial neoplasia

Annals of the New York Academy of Sciences

Volumn 1171, Issue , 2009, Pages 100-104

  No, Jae Hong ^a   Jo, Hoenil ^a   Kim, Su Hyeong ^a   Park, In Ae ^a   Kang, Daehee ^a   Lee, Chae Hyeong ^b   Han, Seung Su ^b   Kim, Jae Weon ^a   Park, Noh Hyun ^a   Kang, Soon Beom ^a   Song, Yong Sang ^a,c  

^a Seoul National University College of Medicine   (South Korea)

^b Dongguk University Ilsan Hospital   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Cervical intraepithelial neoplasia; Matrix metalloproteinase; Urokinase type plasminogen activator

Indexed keywords

ENZYME ANTIBODY; GELATINASE A; GELATINASE B; PARAFFIN; UROKINASE;

CANCER GRADING; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONFERENCE PAPER; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PROTEIN EXPRESSION; UTERINE CERVIX CARCINOMA IN SITU;

EID: 69149110462     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04898.x     Document Type: Conference Paper

References (18)

1. Sankaranarayanan, R. J. Ferlay. 2006. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract. Res. Clin. Obstet. Gynaecol. 20 : 207 225.
2. Snijders, P.J. et al. 2006. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J. Pathol. 208 : 152 164.
3. Deryugina, E.I. J.P. Quigley. 2006. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 25 : 9 34.
4. Lijnen, H.R. 2002. Matrix metalloproteinases and cellular fibrinolytic activity. Biochemistry (Mosc). 67 : 92 98.
5. Pepper, M.S. 2001. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler. Thromb. Vasc. Biol. 21 : 1104 1117.
6. Rundhaug, J.E. 2005. Matrix metalloproteinases and angiogenesis. J. Cell. Mol. Med. 9 : 267 285.
7. Obermair, A. et al. 1997. Correlation of vascular endothelial growth factor expression and microvessel density in cervical intraepithelial neoplasia. J. Natl. Cancer Inst. 89 : 1212 1217.
8. Overall, C.M. O. Kleifeld. 2006. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer 6 : 227 239.
9. Guidi, A.J. et al. 1995. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J. Natl. Cancer Inst. 87 : 1237 1245.
10. Davidson, B. et al. 1999. MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma - a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol. Oncol. 73 : 372 382.
11. Heppner, K.J. et al. 1996. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am. J. Pathol. 149 : 273 282.
12. Asha Nair, S. et al. 2003. Changes in matrix metalloproteinases and their endogenous inhibitors during tumor progression in the uterine cervix. J. Cancer Res. Clin. Oncol. 129 : 123 131.
13. Yang, S.F. et al. 2007. A significant elevation of plasma level of matrix metalloproteinase-9 in patients with high-grade intraepithelial neoplasia and early squamous cell carcinoma of the uterine cervix. Reprod. Sci. 14 : 710 718.
14. Gaiotto, M.A. et al. 2004. Comparative study of MMP-2 (matrix metalloproteinase 2) immune expression in normal uterine cervix, intraepithelial neoplasias, and squamous cells cervical carcinoma. Am. J. Obstet. Gynecol. 190 : 1278 1282.
15. Branca, M. et al. 2006. Matrix metalloproteinase-2 (MMP-2) and its tissue inhibitor (TIMP-2) are prognostic factors in cervical cancer, related to invasive disease but not to high-risk human papillomavirus (HPV) or virus persistence after treatment of CIN. Anticancer Res. 26 : 1543 1556.
16. Brummer, O. et al. 2002. MMP-1 and MMP-2 in the cervix uteri in different steps of malignant transformation - an immunohistochemical study. Gynecol. Oncol. 84 : 222 227.
17. Talvensaari, A. et al. 1999. Matrix metalloproteinase 2 immunoreactive protein appears early in cervical epithelial dedifferentiation. Gynecol. Oncol. 72 : 306 311.
18. Daneri-Navarro, A. et al. 1998. Urokinase-type plasminogen activator and plasminogen activator inhibitors (PAI-1 and PAI-2) in extracts of invasive cervical carcinoma and precursor lesions. Eur. J. Cancer 34 : 566 569.